Page last updated: 2024-12-06

2-amino-1,3,4-thiadiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Amino-1,3,4-thiadiazole is a heterocyclic compound that has been extensively studied for its various biological activities. It acts as a building block for the synthesis of a wide range of pharmaceuticals and agrochemicals. The compound exhibits antifungal, antibacterial, and anti-inflammatory properties. It is also known to inhibit the growth of cancer cells. 2-Amino-1,3,4-thiadiazole has shown promise as a lead compound for the development of new drugs for the treatment of various diseases. Its unique structure and diverse biological activities make it a valuable target for pharmaceutical research.'

2-amino-1,3,4-thiadiazole: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID19909
CHEMBL ID1650237
SCHEMBL ID26211
MeSH IDM0056703

Synonyms (64)

Synonym
EN300-17228
[1,3,4]-thiadiazol-2-ylamine
BB 0217149
[1,3,4]thiadiazol-2-ylamine
bdbm50335110
nsc4728 ,
1,4-thiadiazole, 2-amino
fda 0084
nsc-4728
nsc 4728
2-amino-1-thia-3,4-diazole
aminothiadiazole
1,4-thiadiazol-2-amine
2-amino-1,4-thiadiazole
1,4-thiadiazole, 2-amino-
x 26
4005-51-0
tf 128
atda
NCI60_004114
NCIMECH_000679
3h-1,3,4-thiadiazol-2-imine
1,3,4-thiadiazol-2-amine
2-amino-1,3,4-thiadiazole, 97%
einecs 223-657-7
ai3-50581
2-amino-1,3,4-thiadiazole
1,3,4-thiadiazole, 2-amino-
brn 0107135
STK398099
A1060
AKOS000100062
inchi=1/c2h3n3s/c3-2-5-4-1-6-2/h1h,(h2,3,5)
qukglncxgvwcjx-uhfffaoysa-
CHEMBL1650237 ,
6-methyl-2-[4-(2,4,6-trioxohexahydropyrimidin-5-yl)azophenyl]-1,3-benzothiazole-7-sulfonic acid;1,3,4-thiadiazol-2-amine
A824876
CCG-35854
unii-6l41aok74p
6l41aok74p ,
BP-10045
FT-0611004
NF-0014
SCHEMBL26211
tf-128
x-26
1,3,4-thiadiazol-2-ylamine
1,3,4-thiadiazole-2-amine
2-amino-1,3,4-thiadiazol
1,3,4-thiadiazol-5-amine
J-640145
W-106393
AC-25689
mfcd00003107
J-800149
DTXSID50193113
CS-W019584
F1791-0951
1,3,4-thiadiazolium-2-aminide
AMY3973
D77857
amino-[1,3,4]thiadiazole
Q27265082
Z56899142

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Twenty-one evaluable patients with advanced carcinoma of the endometrium were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly."( Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group.
Asbury, RF; Blessing, JA; Hanjani, P; McGuire, WP; Mortel, R, 1990
)
0.28
"Twenty-six evaluable patients with advanced nonsquamous cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly."( Aminothiadiazole (NSC 4728) in patients with advanced nonsquamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
Asbury, RF; Blessing, JA; DiSaia, PJ; Malfetano, J, 1989
)
0.28
"Twenty-one evaluable patients with advanced squamous-cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly."( Aminothiadiazole (NSC #4728) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group.
Asbury, RF; Blessing, JA; Homesley, HD; Malfetano, J; Mortel, R, 1987
)
0.27
"Thirty-two evaluable patients with advanced epithelial ovarian cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly."( Aminothiadiazole (NSC 4728) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.
Asbury, RF; Blessing, JA; Buchsbaum, HJ; DiSaia, PJ; Wilson, J, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pteridine reductase 1Leishmania majorIC50 (µMol)5,600.00002.95002.95002.9500AID554308
Pteridine reductase 1Leishmania majorKi436.00000.03901.57184.0000AID554309
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID756690Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs relative to control2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID554311Inhibition of Leishmania major DHFR at 500 uM2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID554309Inhibition of Leishmania major PTR1 by Lineweaver-Burk analysis2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID756686Activation of AMPKalpha in rat L6 cells assessed as phosphorylation at Thr172 after 40 mins to 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID554308Inhibition of Leishmania major PTR12011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID756681Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs in presence of insulin2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID554317Inhibition of human DHFR at 1 mM2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (39.29)18.7374
1990's7 (12.50)18.2507
2000's5 (8.93)29.6817
2010's19 (33.93)24.3611
2020's3 (5.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.98 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index33.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (12.07%)5.53%
Reviews5 (8.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (79.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]